Medpace Holdings Stock Alpha and Beta Analysis
| MEDP Stock | USD 324.95 7.02 2.21% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Medpace Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Medpace Holdings over a specified time horizon. Remember, high Medpace Holdings' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Medpace Holdings' market risk premium analysis include:
Beta 0.57 | Alpha (0.02) | Risk 2.03 | Sharpe Ratio (0.05) | Expected Return (0.1) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Medpace |
Medpace Holdings Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Medpace Holdings market risk premium is the additional return an investor will receive from holding Medpace Holdings long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Medpace Holdings. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Medpace Holdings' performance over market.| α | -0.02 | β | 0.57 |
Medpace Holdings expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Medpace Holdings' Buy-and-hold return. Our buy-and-hold chart shows how Medpace Holdings performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Medpace Holdings Market Price Analysis
Market price analysis indicators help investors to evaluate how Medpace Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Medpace Holdings shares will generate the highest return on investment. By understating and applying Medpace Holdings stock market price indicators, traders can identify Medpace Holdings position entry and exit signals to maximize returns.
Medpace Holdings Return and Market Media
The median price of Medpace Holdings for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 342.07 with a coefficient of variation of 2.73. The daily time series for the period is distributed with a sample standard deviation of 9.29, arithmetic mean of 340.69, and mean deviation of 7.34. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | MultiPlan Soars 15.5 percent Is Further Upside Left in the Stock | 01/14/2025 |
2 | Medical Device CRO Market Industry Trends and Global Forecasts 2024-2035, Profiles of Avania, Charles River, CROMSOURCE, CSSi LifeSciences, Eurofins, IQVIA, Med... | 01/31/2025 |
3 | Stephens Investment Management Group LLC Buys 18,786 Shares of Medpace Holdings, Inc. | 02/10/2025 |
4 | Medpace Holdings, Inc. A Bull Case Theory | 02/14/2025 |
5 | Medpace Holdings, Inc. Shares Sold by Rice Hall James Associates LLC - MarketBeat | 02/21/2025 |
6 | Disposition of 8127 shares by Carley Brian T of Medpace Holdings at 42.62 subject to Rule 16b-3 | 02/24/2025 |
7 | Medpace Holdings Director Makes a Major Stock Sale - TipRanks | 02/26/2025 |
8 | Acquisition by Stephen Ewald of tradable shares of Medpace Holdings at 326.11 subject to Rule 16b-3 | 02/27/2025 |
9 | Acquisition by Mccarthy Cornelius P. Iii of tradable shares of Medpace Holdings subject to Rule 16b-3 | 02/28/2025 |
10 | Medpace Holdings Insiders Sell US187m Of Stock, Possibly Signalling Caution | 03/04/2025 |
11 | Plato Investment Management Ltd Decreases Stock Holdings in Medpace Holdings, Inc. | 03/06/2025 |
12 | Disposition of 84770 shares by Troendle August J. of Medpace Holdings at 107.93 subject to Rule 16b-3 | 03/07/2025 |
13 | Taika Capital LP Makes New 369,000 Investment in Medpace Holdings, Inc. | 03/10/2025 |
14 | Options Movement At Medpace Hldgs August J Troendle Exercises Worth 95.92M | 03/11/2025 |
15 | Acquisition by Kraft Robert O. of tradable shares of Medpace Holdings subject to Rule 16b-3 | 03/13/2025 |
About Medpace Holdings Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Medpace or other stocks. Alpha measures the amount that position in Medpace Holdings has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 63.35 | 57.75 | 51.3 | 71.74 | PTB Ratio | 17.8 | 16.85 | 12.46 | 13.08 |
Medpace Holdings Upcoming Company Events
As portrayed in its financial statements, the presentation of Medpace Holdings' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Medpace Holdings' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Medpace Holdings' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Medpace Holdings. Please utilize our Beneish M Score to check the likelihood of Medpace Holdings' management manipulating its earnings.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 22nd of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Medpace Holdings
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Medpace Stock Analysis
When running Medpace Holdings' price analysis, check to measure Medpace Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medpace Holdings is operating at the current time. Most of Medpace Holdings' value examination focuses on studying past and present price action to predict the probability of Medpace Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medpace Holdings' price. Additionally, you may evaluate how the addition of Medpace Holdings to your portfolios can decrease your overall portfolio volatility.